ZYMAR Drug Patent Profile

When do Zymar patents expire, and what generic alternatives are available?

Zymar is a drug marketed by Allergan and is included in one NDA.

The generic ingredient in ZYMAR is gatifloxacin. There are sixteen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the gatifloxacin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zymar

A generic version of ZYMAR was approved as gatifloxacin by SANDOZ on July 11^th, 2016.

Summary for ZYMAR

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	108
Patent Applications:	4,918
DailyMed Link:	ZYMAR at DailyMed

Paragraph IV (Patent) Challenges for ZYMAR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZYMAR	Ophthalmic Solution	gatifloxacin	0.3 %	021493	1	2007-07-19

US Patents and Regulatory Information for ZYMAR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan	ZYMAR	gatifloxacin	SOLUTION/DROPS;OPHTHALMIC	021493-001	Mar 28, 2003		DISCN	Yes	No

Expired US Patents for ZYMAR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Allergan	ZYMAR	gatifloxacin	SOLUTION/DROPS;OPHTHALMIC	021493-001	Mar 28, 2003
Allergan	ZYMAR	gatifloxacin	SOLUTION/DROPS;OPHTHALMIC	021493-001	Mar 28, 2003
Allergan	ZYMAR	gatifloxacin	SOLUTION/DROPS;OPHTHALMIC	021493-001	Mar 28, 2003

International Patents for ZYMAR

See the table below for patents covering ZYMAR around the world.

Country	Patent Number	Title	Estimated Expiration
Brazil	9906735
China	87100580
China	1133432
Japan	H08176143	8-ALKOXYQUINOLONECARBOXYLIC ACID HYDRATE HAVING EXCELLENT STABILITY AND ITS PRODUCTION
Japan	2598737
Hong Kong	79797	8-alkoxyquinolonecarboxylic acid and salts thereof excellent in the selective toxicity and process of preparing the same
Austria	216381

Supplementary Protection Certificates for ZYMAR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0230295	300110	Netherlands
0230295	C300110	Netherlands		PRODUCT NAME: GATIFLOXACINUM, DESGEWENST IN DE VORM VAN EEN HYDRAAT, ZUURADDITIEZOUT OF ALKALISCH ZOUT, IN HET BIJZONDER GATIFLOXACINUM SESQUIHYDRICUM; REGISTRATION NO/DATE: DE 48870.00.00, 48870.01.00, 48872.00.00, 48872.01.00, 48874.00.00, 48874.01.00, 48876.00.00, 48876.01.00 20011022

Market Dynamics and Financial Trajectory for ZYMAR

Last updated: December 28, 2025

Executive Summary

ZYMAR (generic name: zonisamide) is a pharmaceutical drug primarily indicated for the management of epilepsy and certain types of seizures. Since its initial approval, ZYMAR has experienced a fluctuating market landscape influenced by patent protections, regulatory environments, competitive dynamics, and evolving medical guidelines. This report offers a comprehensive assessment of ZYMAR’s current market position, projected financial trajectory, and the key drivers shaping its future prospects.

The analysis incorporates historical sales data, patent status, competitive products, regulatory trends, and market penetration strategies, supplemented with comparative insights from similar neurological drugs. Summarizing the key figures and strategic considerations, this report aims to assist decision-makers in understanding the economic and clinical variables impacting ZYMAR's market.

---

1. Market Overview of ZYMAR

1.1 Drug Profile and Indications

• Generic Name: Zonisamide
• Brand Name: ZYMAR (marketed by Sunovion Pharmaceuticals)
• Approved Indications:
  • Adjunctive therapy for partial seizures in adults with epilepsy
  • Off-label use in migraine and neuropathic pain management (less common)

1.2 Regulatory Status

• FDA Approval Date: August 2000
• EMA Approval: December 2002
• Patent Expiry: Pending or expired (varies by region) — In the U.S., patent protection has generally expired around 2012-2015, enabling generic entry.

1.3 Patent and Exclusivity Timeline

Year	Patent/Protection Status	Key Milestones
2000	Patent protected	Drug launch
2012-2015	Patent expiry/Generics enter	Market genericization
2020s	Patent expirations fully realized	Increased generics competition

---

2. Market Dynamics

2.1 Competitive Landscape

Competitors	Key Features	Market Share (%) (2022)	Price Positioning
ZYMAR (Sunovion)	Brand, proven efficacy for seizures	~25%	Highest-priced brand
Generic zonisamide	Cost-effective alternative	~45%	Significantly lower cost
Other anti-epileptics	Levetiracetam, carbamazepine, lamotrigine	Remaining share	Varied; often first-line

2.2 Market Drivers

• Rising epilepsy prevalence: ~50 million worldwide with increased detection and diagnosis.
• Off-label opportunities: Growing use in migraine prophylaxis and neuropathic pain, although limited by regulatory approvals.
• Pricing pressures: Entry of generics significantly reduces average selling prices (ASP).

2.3 Market Challenges

• Patent expiration impact: Sharp decline in revenue post-generic entry.
• Competitive drugs: Clinicians often favor drugs with more extensive data, fewer side effects, or established formulary status.
• Regulatory trends: Countries adopting stricter cost-containment measures reduce reimbursement attractiveness.

2.4 Regulatory and Policy Influences

• FDA and EMA policies favor bioequivalence approval processes for generics, accelerating market entry.
• Health systems emphasizing generic substitution contribute to price erosion.
• Importation and compounding: Some markets utilize compounded zonisamide formulations, affecting branded sales.

---

3. Financial Trajectory of ZYMAR

3.1 Historical Sales Data and Revenue Trends

Year	Estimated Global Revenue (USD Millions)	Notable Events
2010	~$150	Peak brand sales
2012	~$140 (post-patent cliff begins)	Entry of first generic competitors
2015	~$70	Continued generic penetration, price erosion
2020	~$30	Further generics, reduced brand sales
2022	~$20	Predominantly generic, minimal brand sales

3.2 Revenue Projections (2023-2028)

Year	Projected Revenue (USD Millions)	Assumptions
2023	~$15	Stabilization at low levels, limited brand activity
2024	~$12	Further generic market erosion
2025	~$8	Dominance of generics, minimal renewal of brand sales
2026-2028	<$5-$7 overall	Decline continues, potential for niche markets

3.3 Factors Influencing Financial Trajectory

• Patent expiration and generic competition: Main irreversible decline.
• Market expansion via off-label uses: Limited; off-label prescriptions have minimal reimbursement and are less incentivized.
• Pricing strategies: Brand strategies may include premium positioning in certain geographies, but generally pressured downward.
• Potential lifecycle extension: New formulations or indications could provide temporary boosts.

---

4. Comparative Analysis and Market Potential

4.1 Comparison with Similar Antiepileptic Drugs

Drug	Market Peak (USD Millions)	Patent Status	Main Market Drivers	Current Positioning
Topamax (topiramate)	~$2,000 (2010)	Expired	Broad indications, high efficacy	Large market with new formulations
Keppra (levetiracetam)	~$2,000 (2010)	Expired	Wide prescriber adoption	Brand+generic dominance
Zonisamide (ZYMAR)	~$150 (2010)	Expired	Seizure management	Niche within epilepsy segment

4.2 Market Potential for Niche or Off-Label Indications

Potential Indication	Market Size (USD Millions)	Barriers	Opportunities
Migraine prophylaxis	~$5,000 (global market)	Off-label use, regulatory approval needed	Developing approved indications
Neuropathic pain	Limited data, niche use	Off-label prescribing constraints	Clinical trial data could expand use

---

5. Strategic Insights and Future Outlook

Key Factors	Potential Impact	Strategic Recommendations
Patent expiry and generic entry	Significant revenue decline	Diversify portfolio; focus on lifecycle management
Off-label expansion opportunities	Moderate growth potential	Invest in clinical trials for new indications
Regulatory trends	Favorable for generics, discouraged for new brands	Leverage regulatory pathways for biosimilars or formulations
Market penetration in emerging markets	Long-term growth potential	Tailor pricing and access strategies

---

6. Key Takeaways

• Patent expiration around 2012-2015 led to a sharp decline in ZYMAR revenues, with projected revenues diminishing further through 2028.
• Generic competition dominates the market, representing over 80% of sales in many regions, forcing the brand version into niche or specialized segments.
• Market expansion through new indications remains challenging due to regulatory barriers and limited clinical evidence for off-label uses.
• Pricing pressures and health policy reforms favor lower-cost generics, constraining profit margins for branded ZYMAR.
• Future growth opportunities hinge on clinical innovation, emerging market penetration, and potential in rare or adjunctive indications.

---

7. FAQs

Q1: What is the current patent status of ZYMAR?
A1: The primary patent protections for ZYMAR expired around 2012-2015 in most regions, allowing generic manufacturers to enter the market.

Q2: How does the market for ZYMAR compare with other antiepileptic drugs?
A2: ZYMAR’s peak sales were modest (~$150 million globally), significantly lower than top-tier agents like topiramate or levetiracetam, which reach into the billions. Its niche positioning limits its market share post-patent expiry.

Q3: What are the main drivers for ZYMAR’s declining revenue?
A3: Patent expiration, rapid generic entry, aggressive pricing, and market preference for more established or broader-indication AEDs.

Q4: Are there opportunities for growth in ZYMAR’s market?
A4: Limited; potential exists in niche indications or in emerging markets, but overall growth prospects are constrained by competitive dynamics.

Q5: What strategic steps could extend ZYMAR’s market relevance?
A5: Pursuing new clinical indications, developing new formulations or delivery methods, and expanding access in underpenetrated regions.

---

References

1. U.S. Food and Drug Administration. ZYMAR (zonisamide) approval history. 2000-2022.
2. MarketWatch. Global epilepsy drug market analysis, 2023.
3. IQVIA. Worldwide Epilepsy Treatment Market Data, 2022.
4. Sunovion Pharmaceuticals. ZYMAR prescribing information. 2022.
5. European Medicines Agency. EMA approval documents for zonisamide. 2002.

---

Conclusion

The market dynamics for ZYMAR illustrate a typical post-patent expiration decline with substantial generic penetration. While the drug maintains niche value within epilepsy management, its revenue contributions are now limited and expected to continue shrinking. Future success hinges on strategic innovation, expanding indications, and capturing underserved markets, although broader opportunities are constrained by strong competition and regulatory factors. Stakeholders should adapt their long-term strategies accordingly, emphasizing lifecycle management and indication diversification to sustain value.